Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study

Rha, S. Y.; Wyrwicz, L. S.; Weber, P. E. Y.; Bai, Y.; Ryu, M. H.; Lee, J.; Rivera, F.; Alves, G. V.; Garrido, M.; Shiu, K. -k.; Fernandez, M. Gonzalez; Li, J.; Lowery, M.; Cil, T.; Cruz, F. J. S. M.; Qin, S.; Yin, L.; Bordia, S.; Bhagia, P.; Oh, D-y.

doi:10.1016/j.annonc.2023.01.006

YUHSpace

BROWSE

0 303

Cited 56 times in

Cited 0 times in

Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study

Authors: Rha, S. Y. ; Wyrwicz, L. S. ; Weber, P. E. Y. ; Bai, Y. ; Ryu, M. H. ; Lee, J. ; Rivera, F. ; Alves, G. V. ; Garrido, M. ; Shiu, K. -k. ; Fernandez, M. Gonzalez ; Li, J. ; Lowery, M. ; Cil, T. ; Cruz, F. J. S. M. ; Qin, S. ; Yin, L. ; Bordia, S. ; Bhagia, P. ; Oh, D-y.